最新临床数据显示，Biomerica公司开发的肠易激综合征治疗方案InFoods®展现出显著疗效。在真实世界应用场景中，接近六成接受该疗法的患者实现了具有临床意义的疼痛缓解，同时有超过三分之二的患者腹胀症状得到明显改善。
这项突破性疗法通过精准识别引发患者症状的特定食物抗体，为个体化治疗提供了新范式。研究结果表明，该疗法不仅能有效缓解肠易激综合征的核心症状，更为长期受困于该疾病的患者带来了新的治疗希望。
最新临床数据显示，Biomerica公司开发的肠易激综合征治疗方案InFoods®展现出显著疗效。在真实世界应用场景中，接近六成接受该疗法的患者实现了具有临床意义的疼痛缓解，同时有超过三分之二的患者腹胀症状得到明显改善。
这项突破性疗法通过精准识别引发患者症状的特定食物抗体，为个体化治疗提供了新范式。研究结果表明，该疗法不仅能有效缓解肠易激综合征的核心症状，更为长期受困于该疾病的患者带来了新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.